Cellcept 500 Mg 50 Tab

Cellcept 500 Mg 50 Tab

Description:

Cellcept 500 mg 50 tab is a prescription immunosuppressive medicine containing mycophenolate mofetil, used to help prevent organ rejection in patients who have received an allogeneic renal, cardiac, or hepatic (kidney, heart, or liver) transplant. It is classified as a systemic immunosuppressant and is always used in combination with other anti-rejection medicines such as cyclosporine and corticosteroids. By selectively inhibiting the proliferation of T and B lymphocytes, Cellcept reduces the immune system’s ability to attack the transplanted organ, helping to maintain long-term graft function and survival. This product is intended for adult and adolescent transplant patients under strict medical supervision.

Indications:

• Prophylaxis (prevention) of acute organ rejection in patients receiving allogeneic renal (kidney) transplants.
• Prophylaxis of organ rejection in patients receiving allogeneic cardiac (heart) transplants.
• Prophylaxis of organ rejection in patients receiving allogeneic hepatic (liver) transplants.
• Used as part of a combination immunosuppressive regimen with cyclosporine and corticosteroids.
• Helps reduce immune-mediated damage to the transplanted organ, thereby supporting graft survival and function.

Active Ingredients / Key Components:

• Mycophenolate mofetil – 500 mg per tablet.
• Inactive ingredients/excipients: Full excipient list is not provided in the available information (For full ingredient information, please check the product leaflet or the manufacturer’s official website.). Refer to the official package insert for complete details.

Dosage & Administration / How to Use:

• Cellcept 500 mg tablets must be used exactly as prescribed by a transplant specialist or healthcare provider experienced in immunosuppressive therapy.
• Typical adult renal transplant dose (example, not a substitute for prescription): often initiated within 72 hours of transplantation, usually 1 g twice daily (total 2 g/day) or as directed by the physician. Actual dose may vary by organ type, patient weight, and clinical status.
• Tablets should be swallowed whole with a glass of water; do not crush or chew to avoid unnecessary exposure to the active ingredient.
• May be taken with or without food; taking consistently in the same way (always with food or always without food) is recommended to maintain stable absorption. Follow your doctor’s advice.
• If a dose is missed, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose to make up for a missed dose.
• Therapy is usually long term and continuous to maintain prevention of rejection, unless your doctor decides to adjust or stop treatment.
• Regular monitoring of blood counts, liver and kidney function, and drug levels (for concomitant medicines) is required during treatment.
• Use in children and adolescents: dosing is weight-based and must be strictly determined by a pediatric transplant specialist.

Clinical Benefits:

• Provides effective immunosuppression to help prevent acute organ rejection after kidney, heart, or liver transplantation.
• Acts selectively on T and B lymphocytes by inhibiting inosine monophosphate dehydrogenase (IMPDH), reducing the proliferation of immune cells responsible for graft rejection.
• Helps maintain long-term graft function and improves the chances of transplant success when used as part of a combination regimen.
• Allows for a more targeted immunosuppressive effect on lymphocytes, as other cell types can use salvage pathways for purine synthesis, potentially reducing some off-target effects.

Warnings & Contraindications:

• Cellcept (mycophenolate mofetil) is a potent immunosuppressive medicine and should only be used under the supervision of a specialist experienced in transplant management.
• Contraindications: Known hypersensitivity to mycophenolate mofetil, mycophenolic acid, or any component of the formulation. Contraindicated in pregnancy unless no suitable alternative is available and the potential benefit justifies the potential risk to the fetus.
• Pregnancy and fertility: Mycophenolate is associated with an increased risk of congenital malformations and pregnancy loss. Effective contraception is required for women of childbearing potential before, during, and for a period after treatment, as advised by the doctor. Men taking mycophenolate should also follow contraception advice given by their physician.
• Infections: Increases the risk of serious, sometimes life-threatening infections, including opportunistic infections, sepsis, and reactivation of latent infections (e.g., tuberculosis, hepatitis B/C, herpes viruses). Report fever, sore throat, persistent cough, or any signs of infection immediately.
• Malignancy risk: Long-term immunosuppression may increase the risk of lymphomas and skin cancers. Avoid excessive sun exposure and use high-SPF sunscreen and protective clothing.
• Hematologic effects: May cause neutropenia, anemia, thrombocytopenia, or pancytopenia. Regular complete blood count (CBC) monitoring is required. Inform your doctor if you notice unusual bruising, bleeding, or persistent fatigue.
• Gastrointestinal effects: Use with caution in patients with active serious digestive system disease (e.g., active peptic ulcer, inflammatory bowel disease) as it may worsen symptoms.
• Vaccinations: Live vaccines should be avoided during treatment. Response to vaccines may be reduced due to immunosuppression.
• Consult your doctor before use if pregnant, planning pregnancy, nursing, taking other immunosuppressants, or if you have liver disease, kidney disease, history of serious infections, or blood disorders.
• Do not stop or change the dose of Cellcept without medical advice, as this may increase the risk of organ rejection.
• Keep out of reach of children.

Side Effects:

• Common side effects: Nausea, vomiting, diarrhea, abdominal pain, constipation, headache, tremor, insomnia, cough, increased risk of infections (e.g., respiratory or urinary tract infections).
• Hematologic side effects: Anemia, leukopenia (low white blood cells), neutropenia, thrombocytopenia. Regular blood tests are necessary to monitor these effects.
• Serious side effects (seek immediate medical attention): Signs of severe infection (high fever, chills, persistent sore throat, shortness of breath), unexplained bruising or bleeding, severe abdominal pain, black or bloody stools, yellowing of the skin or eyes (jaundice), severe allergic reactions (rash, itching, swelling of face or throat, difficulty breathing).
• Long-term use may increase the risk of certain cancers, particularly lymphomas and skin cancers. Report any unusual lumps, persistent skin lesions, or changes in moles to your doctor.

Storage Instructions:

Store in a cool, dry place away from direct sunlight and moisture. Keep the blister pack or bottle tightly closed. Do not store above the temperature specified in the official package insert (typically below 25°c or as directed by the manufacturer). Keep out of reach of children. Do not use after the expiry date printed on the pack. Dispose of unused or expired medicine according to pharmacist or local regulations; do not throw in household waste or wastewater.

Specifications:

• Form: film-coated tablets.
• Strength: 500 mg mycophenolate mofetil per tablet.
• Pack size: 50 tablets per pack.
• Route of administration: oral.
• Intended use: prescription-only immunosuppressive medicine for transplant patients.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.